Article Sidebar

PDF (Tiếng Việt)
Published: 2025-03-26
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v188i3.3076
Issue
Vol. 188 No. 3 (2025)
Section
Các bài báo
How to Cite
Long, Đường M. ., Tuyển, Đỗ G. ., Dũng, N. T. ., & Hà, Đặng T. V. . (2025). Assessment of lipid metabolism disorders and plasma atherosclerosis index in adult patients with lupus nephritis. Journal of Medical Research, 188(3), 71-82. https://doi.org/10.52852/tcncyh.v188i3.3076

Assessment of lipid metabolism disorders and plasma atherosclerosis index in adult patients with lupus nephritis

Duong Manh Long, Do Gia Tuyen, Nghiem Trung Dung, Dang Thi Viet Ha

Main Article Content

Abstract

A cross-sectional study was conducted on 40 patients with lupus nephritis at the Nephro - Urology and Dialysis Center - Bach Mai Hospital to determine the proportion of dyslipidemia and atherogenic index of plasma (AIP) in this group of patients. All patients had at least one lipid metabolism disorder. Hypertriglyceridemia was the most common disorder, found in 90% of patients. The rates of abnormal cholesterol, LDL-C, HDL-C were 77.5%; 85%; 72.5%, respectively. The average AIP index of the study group was 0.44 ± 0.39; 73% of patients had an AIP score > 2.1. HDL concentration was positively correlated with complement C3 level (r = 0.610; p < 0.001). AIP index was negatively correlated with complement C3 level (r = -0.525, p < 0.001) and C4 level (r = -0.454; p = 0.003).

Article Details

Keywords

Lipid metabolism disorders, atherogenic index of plasma, lupus nephritis, systemic lupus erythematosus

References

1. Dall’Era M. Chapter 21. Systemic Lupus Erythematosus. In: Imboden JB, Hellmann DB, Stone JH, eds. CURRENT Diagnosis & Treatment: Rheumatology. 3rd ed. The McGraw-Hill Companies; 2013. Accessed October 5, 2024. accessmedicine.mhmedical.com/content.aspx?aid=57272268
2. Rovin BH, Ayoub IM, Chan TM, et al. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney International. 2024;105(1):S1-S69. doi:10.1016/j.kint.2023.09.002
3. Tselios K, Koumaras C, Gladman DD, et al. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45(5):604-610. doi:10.1016/j.semarthrit.2015.10.010
4. Olusi SO, George S. Prevalence of LDL atherogenic phenotype in patients with systemic lupus erythematosus. Vasc Health Risk Manag. 2011;7:75-80. doi:10.2147/VHRM.S17015
5. Wijaya LK, Kasjmir YI, Sukmana N, et al. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones. 2005;37(3):132--44.
6. Chong YB, Yap DYH, Tang CSO, et al. Dyslipidaemia in patients with lupus nephritis. Nephrology (Carlton). 2011;16(5):511-517. doi:10.1111/j.1440-1797.2011.01456.x
7. Guo H, Peng C, Zhang M, et al. Dyslipidemia and important organ damages in patients with active systemic lupus erythematosus. Chinese Journal of Rheumatology. 2010;33-36. http://dx.doi.org/10.3760/cma.j.issn.1007-7480.2010.01.009
8. Yu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study. Atherosclerosis. 2015;243(1):11-18. doi:10.1016/j.atherosclerosis.2015.08.030
9. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Medical Journal of the Islamic Republic of Iran. 2015;29:240. Accessed November 10, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC4715400/
10. Dobiásová M, Frohlich J, Sedová M, et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566-571. doi:10.1194/jlr.P011668
11. Dobiásová M. AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006;52(1):64-71.
12. Mok CC. Prognostic factors in lupus nephritis. Lupus. 2005;14(1):39-44. doi:10.1191/0961203305lu2057oa
13. Ballard-Hernandez J, Sall J. Dyslipidemia Update. Nurs Clin North Am. 2023;58(3):295-308. doi:10.1016/j.cnur.2023.05.002
14. Lưu Quang Tiến, Nguyễn Văn Đoàn, Nguyễn Anh Minh. Đặc điểm lâm sàng, cận lâm sàng của bệnh nhân lupus ban đỏ hệ thống có rối loạn lipid máu. Tạp chí Y học Việt Nam. 2023;523(2). doi:10.51298/vmj.v523i2.4558
15. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002;39. Accessed December 18, 2024. https://typeset.io/papers/k-doqi-clinical-practice-guidelines-for-chronic-kidney-22mdhpltbq
16. Sajjad S, Farman S, Saeed MA, et al. Frequency of Dyslipidemia in patients with Lupus Nephritis. Pak J Med Sci. 2017;33(2):358-362. doi:10.12669/pjms.332.12410
17. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240. Accessed November 24, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715400/
18. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. doi:10.1016/j.kint.2016.02.026
19. Kati Ylitalo, Kimmo VK Porkka, Seppo Meri, et al. Serum complement and familial combined hyperlipidemia. Atherosclerosis. 1997;2:271-277. http://ouci.dntb.gov.ua/en/works/7ArJ3pm4/
20. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19(5):478-482. doi:10.1097/MOL.0b013e32830f4a06
21. Parra S, Vives G, Ferré R, et al. Complement system and small HDL particles are associated with subclinical atherosclerosis in SLE patients. Atherosclerosis. 2012;225(1):224-230. doi:10.1016/j.atherosclerosis.2012.08.029
22. Yaël Mamane, Chi Chung Chan, Genevieve Lavallee, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. 2009 Sep;58(9):2006-17. doi: 10.2337/db09-0323